Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

8.69USD
19 Jan 2018
Change (% chg)

$0.16 (+1.88%)
Prev Close
$8.53
Open
$8.55
Day's High
$8.73
Day's Low
$8.37
Volume
200,554
Avg. Vol
310,263
52-wk High
$15.01
52-wk Low
$4.10

Select another date:

Fri, Jan 12 2018

Photo

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

Jan 11 A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

BRIEF-Insys' Treatment For Prader-Willi Syndrome Gets ‘Fast Track’ Designation

* FDA GRANTS INSYS THERAPEUTICS ‘FAST TRACK’ DESIGNATION FOR CANNABIDIOL (CBD) ORAL SOLUTION AS INVESTIGATIONAL TREATMENT FOR PRADER-WILLI SYNDROME

North Carolina accuses drugmaker Insys of scheme to push opioid

BOSTON North Carolina sued Insys Therapeutics Inc on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic.

REFILE-UPDATE 1-North Carolina accuses drugmaker Insys of scheme to push opioid

BOSTON, Dec 21 North Carolina sued Insys Therapeutics Inc on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic.

North Carolina sues drugmaker Insys over role in opioid epidemic

Dec 21 North Carolina on Thursday sued Insys Therapeutics Inc over its role in the opioid epidemic, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys in a quest to make more money.

UPDATE 1-New Mexico adds Insys, Mallinckrodt to opioid epidemic lawsuit

Dec 20 New Mexico on Wednesday added claims against drugmakers Insys Therapeutics Inc and Mallinckrodt Plc in a lawsuit accusing various opioid manufacturers and distributors of helping fuel a drug addiction epidemic in the state.

New Mexico adds Insys, Mallinckrodt to opioid epidemic lawsuit

Dec 20 New Mexico on Wednesday added claims against drugmakers Insys Therapeutics Inc and Mallinckrodt Plc in a lawsuit accusing various opioid manufacturers and distributors of helping fuel a drug addiction epidemic in the state.

BRIEF-Insys Therapeutics Inc - ‍Study Is Expected To Be Completed In Late 2018 For Of Cbd Oral Solution-A​

* INSYS THERAPEUTICS INITIATES PHASE 2 CLINICAL TRIAL OF CANNABIDIOL (CBD) ORAL SOLUTION FOR TREATMENT OF REFRACTORY CHILDHOOD ABSENCE EPILEPSY IN PEDIATRIC PATIENTS

BRIEF-Insys Therapeutics' NDA For Buprenorphine Sublingual Spray Accepted By FDA

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) FOR BUPRENORPHINE SUBLINGUAL SPRAY FROM INSYS THERAPEUTICS

Select another date: